BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3755714)

  • 21. The effect of hypoxic radiosensitizer after mild hyperthermia in C3H mammary carcinoma.
    Ohizumi Y; Murayama C; Maezawa H; Mori T
    Tokai J Exp Clin Med; 1984 Oct; 9(4):331-7. PubMed ID: 6537042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The differential cytotoxicity of RSU 1069: cell survival studies indicating interaction with DNA as a possible mode of action.
    Stratford IJ; Walling JM; Silver AR
    Br J Cancer; 1986 Mar; 53(3):339-44. PubMed ID: 3754453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potentiation of melphalan activity in the KHT sarcoma by the radiosensitizer RSU 1069.
    Siemann DW; Maddison K; Wolf K
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1657-60. PubMed ID: 6548212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Studies on the toxicity of RSU-1069.
    Whitmore GF; Gulyas S
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1219-22. PubMed ID: 3755716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experimental pharmacokinetics of RSU-1069 and its analogues: high tumor/plasma ratios.
    Deacon JM; Holliday SB; Ahmed I; Jenkins TC
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1087-90. PubMed ID: 3755713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiosensitization by a new nucleoside analogue: 1-[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl-2-nitroimidazole (RP-170).
    Murayama C; Suzuki A; Suzuki T; Miyata Y; Sakaguchi M; Tanabe Y; Tanaka N; Mori T
    Int J Radiat Oncol Biol Phys; 1989 Sep; 17(3):575-81. PubMed ID: 2528527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A fluorinated 2-nitroimidazole, KU-2285, as a new hypoxic cell radiosensitizer.
    Sasai K; Nishimoto S; Shimokawa K; Hisanaga Y; Kitakabu Y; Shibamoto Y; Zhou L; Wang J; Takahashi M; Kagiya T
    Int J Radiat Oncol Biol Phys; 1991 Jun; 20(6):1249-54. PubMed ID: 1828462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postirradiation modification of tumor blood flow: a method to increase the effectiveness of chemical radiosensitizers.
    Chaplin DJ
    Radiat Res; 1988 Aug; 115(2):292-302. PubMed ID: 3406369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiosensitization, pharmacokinetics, and toxicity of a 2-nitroimidazole nucleoside (RA-263).
    Agrawal KC; Rupp WD; Rockwell S
    Radiat Res; 1986 Feb; 105(2):227-39. PubMed ID: 3754053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Recent advances in hypoxic cell radiosensitizer].
    Ono K; Takahashi M; Nishidai T; Shibamoto Y; Abe M
    Gan No Rinsho; 1983 Oct; 29(13):1608-12. PubMed ID: 6230470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiosensitization of hypoxic cells in vivo by SR 2508 at low radiation doses: a preliminary report.
    Brown JM; Yu NY
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1207-12. PubMed ID: 6236184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).
    Binger M; Workman P
    Cancer Chemother Pharmacol; 1991; 29(1):37-47. PubMed ID: 1742848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic enhancement of the efficacy of the bioreductively activated alkylating agent RSU-1164 in the treatment of prostatic cancer by photodynamic therapy.
    Henry JM; Isaacs JT
    J Urol; 1989 Jul; 142(1):165-70. PubMed ID: 2733098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells.
    Zeman EM; Brown JM; Lemmon MJ; Hirst VK; Lee WW
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1239-42. PubMed ID: 3744945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancement of DNA damage in mammalian cells upon bioreduction of the nitroimidazole-aziridines RSU-1069 and RSU-1131.
    Jenner TJ; Sapora O; O'Neill P; Fielden EM
    Biochem Pharmacol; 1988 Oct; 37(20):3837-42. PubMed ID: 3190731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiosensitization by a new potent nucleoside analog: 1-(1',3',4'-trihydroxy-2'-butoxy)methyl-2-nitroimidazole(RP-343).
    Murayama C; Suzuki A; Sato C; Tanabe Y; Shoji T; Miyata Y; Nishio A; Suzuki T; Sakaguchi M; Mori T
    Int J Radiat Oncol Biol Phys; 1993 Jun; 26(3):433-43. PubMed ID: 8514541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of misonidazole, SR-2508, RSU-1069 and WR-2721 on spontaneous metastases in C57BL mice.
    Kanclerz A; Chapman JD
    Int J Radiat Oncol Biol Phys; 1988 Feb; 14(2):309-16. PubMed ID: 2828290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Intraarterial infusion of hypoxic radiosensitizer RK28 in rabbit VX2 tumor system].
    Suda H
    Nihon Igaku Hoshasen Gakkai Zasshi; 1991 Jun; 51(6):678-85. PubMed ID: 1886757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Developments in the experimental methods of evaluating hypoxic cell sensitizers].
    Shibamoto Y; Sasai K; Takahashi M; Abe M
    Gan No Rinsho; 1988 Oct; 34(13):1859-63. PubMed ID: 3199519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of the antitumor efficacy of lomustine by the radiosensitizer RSU 1069.
    Siemann DW; Alliet K; Maddison K; Wolf K
    Cancer Treat Rep; 1985 Dec; 69(12):1409-14. PubMed ID: 3841024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.